Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2003
06/18/2003EP1318976A2 Substituted aminopropoxyaryl derivatives useful as agonists for lxr
06/18/2003EP1318839A2 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
06/18/2003EP1318837A2 Method of treating estrogen receptor positive carcinoma
06/18/2003EP1318836A2 Treatment of hyperproliferative diseases
06/18/2003EP1318833A2 Compositions and methods for cell dedifferentiation and tissue regeneration
06/18/2003EP1318829A1 Angiogenic agents and their uses
06/18/2003EP1318827A1 Polymer-modified synthetic proteins
06/18/2003EP1318817A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
06/18/2003EP1318815A2 Use of the combination of nicotinic acid or derivatives with riboflavin in the manufacture of a medicament for the treatment of primary headaches
06/18/2003EP1318814A2 Triazole compounds useful as protein kinase inhibitors
06/18/2003EP1318813A1 Stable pergolide mesylate and process for making same
06/18/2003EP1318811A1 Cyclopentyl modulators of chemokine receptor activity
06/18/2003EP1318806A1 Fatty acid synthase inhibitors
06/18/2003EP1318803A1 Fatty acid synthase inhibitors
06/18/2003EP1318802A2 Substituted hydrazine derivatives
06/18/2003EP1318798A1 Water-soluble prodrugs of propofol for treatment of migraine
06/18/2003EP1318794A2 Method for reducing toxicity of combined chemotherapies
06/18/2003EP1255757B1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors
06/18/2003EP1232247A4 Modulation of signal transduction
06/18/2003EP1171128B1 Combination of n-butyldeoxynojirimycin (nb-dnj) and glycolipid degrading enzymes in therapy
06/18/2003EP1115704B1 Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
06/18/2003EP1102747B1 Crystalline forms of osanetant
06/18/2003EP1075475B1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production
06/18/2003EP1011709A4 Inhibition of apoptotis using prosaposin receptor agonists
06/18/2003EP0819125B1 Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
06/18/2003EP0757677B1 Benzocyclohexylimidazolethione derivatives
06/18/2003EP0749423B1 Piperidines and pyrrolidines
06/18/2003EP0538404B1 Fibroblast growth factor receptors
06/18/2003CN1425073A 病毒株 Strains
06/18/2003CN1425065A Method of controlling telomere length
06/18/2003CN1425021A Gallotannins and ellagitannins as regulators of cytokine release
06/18/2003CN1425016A Benzoxathiepino [3,4-b] pyridine derivatives, process for their preparation and their use as medicaments
06/18/2003CN1425012A Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2
06/18/2003CN1425010A Cyclic compound
06/18/2003CN1425007A Preparation of sulfonamides
06/18/2003CN1425004A N-substituted metal proteinase inhibitor with heterocyclic side chain
06/18/2003CN1425002A Pyrrolidine and piperidine derivatives and their use for treatment of neurodegenerative disorders
06/18/2003CN1424999A Aminoalcohol derivatives
06/18/2003CN1424913A Antivirus medicine
06/18/2003CN1424907A Improved pharmaceutical formulations
06/18/2003CN1424111A Hyacinth bletilla micro-balls for liver and kidney arterial embolism
06/18/2003CN1424107A Medicinal composition for high examination syndromes
06/18/2003CN1424105A Medicinal spray
06/18/2003CN1424103A Chinese medicine for sub-health and its preparing method
06/18/2003CN1424072A Healthy fermentative wine preparation
06/18/2003CN1424064A Healthy medicinal spirit for tonifying kidney and strengthening Yang
06/18/2003CN1424045A Cell growth regulating factor B and preparation thereof
06/18/2003CN1424034A Preparing method of oxiracetam injection and products thereof
06/18/2003CN1424032A Capsule agent with grape-seed extracts as raw material
06/18/2003CN1111529C Piperazino derivatives as neurokinin antagonists
06/18/2003CN1111528C Piperazino derivatives as neurokinin antagonists
06/18/2003CN1111520C Matrix metalloprotease inhibitors
06/18/2003CN1111357C Food products having enhanced cocoa polyphenol content and processes for producing same
06/17/2003US6579989 Sulphostin analogue and process for producing sulphostin and its analogue
06/17/2003US6579983 5-cyano-2-aminopyrimidine derivatives
06/17/2003US6579982 Treating inflammation, cancer
06/17/2003US6579978 Biomaterials comprising N-sulphated hyaluronic acid compounds or derivatives thereof
06/17/2003US6579972 An antibody having a specific binding affinity to a polypeptide of given amino acid sequence; can use in treating diabetes, skeletal muscle diseases, Alzheimer's disease, or peripheral neuropathies with an agonist or antagonist
06/17/2003US6579903 Klainetins and their derivatives, method for their preparation and use thereof
06/17/2003US6579900 Can be used to reduce pain, reducing nausea in an individual undergoing chemotherapy, suppressing appetite, reducing intraocular pressure, and suppressing the immune system in an individual with an organ transplant.
06/17/2003US6579899 Composition for treatment of stress
06/17/2003US6579896 Method for treating allergies using substituted pyrazoles
06/17/2003US6579895 Orally administration to provide a blood plasma concentration profile of celecoxib of at least about 250 mg/ml in not more than about 30 minutes
06/17/2003US6579894 Bactericides, fungicides
06/17/2003US6579893 Related thiazolidinediones
06/17/2003US6579892 Affective disorders; neurotic, stress and somatoform disorders and psychoses, e.g. schizophrenia 3-(3-(6-Methyl-1,2,3,4-tetrahydronaphth-2-ylamino)propylmercap to) -4-methyl-5-phenyl-1,2,4(4H)-triazole
06/17/2003US6579890 Matrix metalloprotease inhibitors
06/17/2003US6579887 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
06/17/2003US6579885 For therapy of attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, Parkinsonism
06/17/2003US6579879 For therapy of diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals
06/17/2003US6579877 Combination of benzoquinazoline antifolates and protecting agents
06/17/2003US6579875 Triazolo-pyridazine derivatives as ligands for GABA receptors
06/17/2003US6579874 Substituted azoles
06/17/2003US6579872 Bezamide derivatives for the treatment of diseases mediated by cytokines
06/17/2003US6579870 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity
06/17/2003US6579869 Cephalotaxanes: their method of preparation and their use in treatment of cancers, leukemias, parasites, including those resistant to usual chemotherapeutic agents, and as reversal agents
06/17/2003US6579858 Use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas
06/17/2003US6579856 Inhibition of stress activated protein kinase (SAPK) pathway and sensitization of cells to cancer therapies
06/17/2003US6579723 Method of recovering highly purified vWF or factor VIII/vWF-complex
06/17/2003US6579684 Assay of YKL-40 as a marker for cancer
06/17/2003US6579522 Replication deficient adenoviral TNF vector
06/17/2003US6579521 Methods of therapy for HIV infection
06/17/2003CA2307553C Citrus peel extract as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
06/17/2003CA2290973C Encapsulated solution dosage forms of sertraline
06/17/2003CA2129820C Dna sequences encoding novel growth/differentiation factors
06/17/2003CA2123315C Therapeutic agents which are antagonists or partial agonists of human interleukin 4
06/17/2003CA2096020C 2.beta.,19-methyleneamino bridged steroids as aromatase inhibitors
06/14/2003CA2364985A1 Imidazo(2,1-b)thiadiazole sulfonamides
06/13/2003WO2003047602A1 Immunostimulatory oligodeoxynucleotides
06/13/2003CA2452909A1 Immunostimulatory oligodeoxynucleotides
06/12/2003WO2003048360A1 NOVEL PROTEINS BINDING TO MAMMALIAN TARGET OF RAPAMYCIN (mTOR) AND GENES THEREOF
06/12/2003WO2003048359A1 Markers for sugar/lipid metabolic disorders and utilization thereof
06/12/2003WO2003048352A2 Histone h3 methyltransferase polypeptide
06/12/2003WO2003048210A1 Fusion protein having enhanced in vivo erythropoietin activity
06/12/2003WO2003048209A1 Bispecific anti-cd19 x anti-cd16 antibodies and uses thereof
06/12/2003WO2003048205A2 Novel proteins with il-6 inhibiting activity
06/12/2003WO2003048199A1 Cytotoxic protein and utilization thereof
06/12/2003WO2003048180A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
06/12/2003WO2003048168A2 Trioxane derivatives as antimalaria or anticancer compounds
06/12/2003WO2003048166A1 Podophyllotoxins as antiproliferative agents
1 ... 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 ... 1564